A Phase 1b, Double Blind, Sponsor Open, Randomized, Parallel, Group Multiple Dose Study Examining The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-06669571 In Subjects With Idiopathic Parkinson's Disease.

Trial Profile

A Phase 1b, Double Blind, Sponsor Open, Randomized, Parallel, Group Multiple Dose Study Examining The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-06669571 In Subjects With Idiopathic Parkinson's Disease.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs PF 6669571 (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 08 Jul 2016 Status changed from recruiting to completed.
    • 03 May 2016 Planned End Date changed from 1 Jul 2016 to 1 May 2016.
    • 03 May 2016 Planned primary completion date changed from 1 Jul 2016 to 1 May 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top